2 ms·
> It's not arbitrary, but it's part of the design of the Phase 3 trial. What I'm trying to understand is if there is any inherent difference that makes one vac
by BurningFrog 6y ago
> It's not arbitrary, but it's part of the design of the Phase 3 trial.
What I'm trying to understand is if there is any inherent difference that makes one vaccine suitable for one dose and another for two doses.
I still haven't seen anything answering this.
- maxerickson 6y agoThey try to work out the immune response in Phase I, and then use that protocol for II and III. I wrote the bit you quote because it gets determined before the efficacy trial. So it isn't arbitrary because they use data to work it out, and then it is sort of fixed once the later phases begin. Given more money and so on they could probably do multiple simultaneous studies. With Covid, a trade-off there would be splitting up the enrollment and slowing down the results. 2 doses triggers a larger immune response, so it is one way to increase the likelihood that the studied dosing is found to be efficacious. And then they are also factoring in other understanding of the immune system, it won't just be about "more is better".
- BurningFrog 6y agoOh, I see: You're saying they use data from Phase 1 to try to infer how many doses would be best. That does make sense, but it must be pretty far from an "exact science". To my (rather recent) understanding, all vaccines benefit from a booster dose. Because that's how the human immune system works.